Neutrophil gelatinase-associated lipocalin in kidney transplantation: A review

Ramirez‐Sandoval, Juan C.; Herrington, William G; Morales‐Buenrostro, Luis E.

doi:10.1016/j.trre.2015.04.004

Cited by 31 publications

(29 citation statements)

References 63 publications

(62 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…, Ramirez‐Sandoval et al . ). It is clear that NGAL is intensely expressed in a dose‐dependent fashion with the severity of kidney disease and is activated at the time of patient presentation, for example in the emergency department (Nickolas et al .…”

Section: Ngalmentioning

confidence: 97%

Biomarkers in acute kidney injury – pathophysiological basis and clinical performance

et al. 2016

View full text Add to dashboard Cite

Various biomarkers of acute kidney injury (AKI) have been discovered and characterized in the recent past. These molecules can be detected in urine or blood and signify structural damage to the kidney. Clinically, they are proposed as adjunct diagnostics to serum creatinine and urinary output to improve the early detection, differential diagnosis and prognostic assessment of AKI. The most obvious requirements for a biomarker include its reflection of the underlying pathophysiology of the disease. Hence, a biomarker of AKI should derive from the injured kidney and reflect a molecular process intimately connected with tissue injury. Here, we provide an overview of the basic pathophysiology, the cellular sources and the clinical performance of the most important currently proposed biomarkers of AKI: neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (KIM-1), liver-type fatty acid-binding protein (L-FABP), interleukin-18 (IL-18), insulin-like growth factor-binding protein 7 (IGFBP7), tissue inhibitor of metalloproteinase 2 (TIMP-2) and calprotectin (S100A8/9). We also acknowledge each biomarker’s advantages and disadvantages as well as important knowledge gaps and perspectives for future studies.

show abstract

Section: Ngalmentioning

confidence: 97%

Biomarkers in acute kidney injury – pathophysiological basis and clinical performance

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Many investigators have examined various patient populations and determined the performance of NGAL. Its performance has been evaluated in various settings, such as for prediction of AKI in pediatric [22] and adult cardiac surgery patients [72,76], in critically ill patients [8,24], in patients in the emergency department [20,21], and in patients in the kidney transplant setting [77][78][79]. A recent meta-analysis by Ho et al including 16 studies with a total of 2906 patients investigated urine NGAL as a biomarker for the prediction of AKI after cardiac surgery in adult patients.…”

Section: Biomarkers Of Akimentioning

confidence: 99%

Biomarkers of acute kidney injury: the pathway from discovery to clinical adoption

Kashani

Cheungpasitporn

Ronco

2017

Clinical Chemistry and Laboratory Medicine (CCLM)

239

197

View full text Add to dashboard Cite

Acute kidney injury (AKI) is a common complication of critical illnesses and has a significant impact on outcomes, including mortality and morbidities. Unfortunately, apart from prophylactic measures, no effective treatment for this syndrome is known. Therefore, early recognition of AKI not only can provide better opportunities for preventive interventions, but also opens many gates for research and development of effective therapeutic options. Over the last few years, several new AKI biomarkers have been discovered and validated to improve early detection, differential diagnosis, and differentiation of patients into risk groups for progressive renal failure, need for renal replacement therapy (RRT), or death. These novel AKI biomarkers complement serum creatinine (SCr) and urine output, which are the standard diagnostic tools for AKI detection. In this article, we review the available literature on characteristics of promising AKI biomarkers that are currently the focus of preclinical and clinical investigations. These biomarkers include neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule 1 (KIM-1), liver-type fatty acid-binding protein, interleukin 18 (lL-18), insulin-like growth factor-binding protein 7, tissue inhibitor of metalloproteinase 2 (TIMP-2), calprotectin, urine angiotensinogen (AGT), and urine microRNA. We then describe the clinical performance of these biomarkers for diagnosis and prognostication. We also appraise each AKI biomarker's advantages and limitations as a tool for early AKI recognition and prediction of clinical outcomes after AKI. Finally, we review the current and future states of implementation of biomarkers in the clinical practice.

show abstract

“…Elevated urinary or serum NGAL levels have been proposed to be an early indicator of immunological rejection after kidney transplant [45].…”

Section: Novel Functions Of Ngal/lipocalinsmentioning

confidence: 99%

Roles of NGAL and MMP-9 in the tumor microenvironment and sensitivity to targeted therapy

Candido

Abrams

Steelman

et al. 2016

Biochimica et Biophysica Acta (BBA) - Molecular Cell Research

View full text Add to dashboard Cite

Various, diverse molecules contribute to the tumor microenvironment and influence invasion and metastasis. In this review, the roles of neutrophil gelatinase-associated lipocalin (NGAL) and matrix metalloproteinase-9 (MMP-9) in the tumor microenvironment and sensitivity to therapy will be discussed. The lipocalin family of proteins has many important functions. For example when NGAL forms a complex with MMP-9 it increases its stability which is important in cancer metastasis. Small hydrophobic molecules are bound by NGAL which can alter their entry into and efflux from cells. Iron transport and storage are also influenced by NGAL activity. Regulation of iron levels is important for survival in the tumor microenvironment as well as metastasis. Innate immunity is also regulated by NGAL as it can have bacteriostatic properties. NGAL and MMP-9 expression may also affect the sensitivity of cancer cells to chemotherapy as well as targeted therapy. Thus NGAL and MMP-9 play important roles in key processes involved in metastasis as well as response to therapy. This article is part of a Special Issue entitled: Tumor Microenvironment Regulation of Cancer Cell Survival, Metastasis, Inflammation, and Immune Surveillance edited by Peter Ruvolo and Gregg L. Semenza.

show abstract

Neutrophil gelatinase-associated lipocalin in kidney transplantation: A review

Cited by 31 publications

References 63 publications

Biomarkers in acute kidney injury – pathophysiological basis and clinical performance

Biomarkers in acute kidney injury – pathophysiological basis and clinical performance

Biomarkers of acute kidney injury: the pathway from discovery to clinical adoption

Roles of NGAL and MMP-9 in the tumor microenvironment and sensitivity to targeted therapy

Contact Info

Product

Resources

About